knowledge -WSS

knowledge

author：comprehensive 2025-08-26 01:32:31 - browse：38

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： NIH chief: government has fallen behind pharma on clinical trials

explore

leisure time

WSS

White House drug czar issues call for 'recovery

Vermont grapples with historic flooding as more rainstorms head for Northeast

Grail's uphill battle for Medicare to cover its cancer screening test

A letter from the executive editor: STAT UnitedHealth investigation

Vermont grapples with historic flooding as more rainstorms head for Northeast

Type 2 diabetes prevention programs work at large scale: study

knowledge

knowledge

focus

Medical records are filled with copy

Type 2 diabetes prevention programs work at large scale: study

Affirmative action in medical school literally saved lives

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Medical records are filled with copy

Watch the official trailer for 'Ahsoka' series

Jerome Adams on the need for new antivirals for Covid

Ventyx halts psoriasis drug development after lackluster trial results

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Cancer diagnosis changes perspective doctor, former hospital CEO

hotspot

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Experimental asthma app from Apple and Anthem shows promise

Experimental asthma app from Apple and Anthem shows promise

White House drug czar issues call for 'recovery

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Inflation cooled significantly in June, bringing price hikes close to normal levels

explore

leisure time

explore

hotspot